IT202200006080A1 - Oral solid composition for the management of neuropathic, osteo-articular, gynecological, post-surgical pain and mitochondrial trophism - Google Patents

Oral solid composition for the management of neuropathic, osteo-articular, gynecological, post-surgical pain and mitochondrial trophism Download PDF

Info

Publication number
IT202200006080A1
IT202200006080A1 IT102022000006080A IT202200006080A IT202200006080A1 IT 202200006080 A1 IT202200006080 A1 IT 202200006080A1 IT 102022000006080 A IT102022000006080 A IT 102022000006080A IT 202200006080 A IT202200006080 A IT 202200006080A IT 202200006080 A1 IT202200006080 A1 IT 202200006080A1
Authority
IT
Italy
Prior art keywords
trophism
osteo
gynecological
neuropathic
articular
Prior art date
Application number
IT102022000006080A
Other languages
Italian (it)
Inventor
Massimo Farinon
Marzio Salvagnin
Original Assignee
Laboratorio Della Farm S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorio Della Farm S P A filed Critical Laboratorio Della Farm S P A
Priority to IT102022000006080A priority Critical patent/IT202200006080A1/en
Publication of IT202200006080A1 publication Critical patent/IT202200006080A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
IT102022000006080A 2022-03-28 2022-03-28 Oral solid composition for the management of neuropathic, osteo-articular, gynecological, post-surgical pain and mitochondrial trophism IT202200006080A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IT102022000006080A IT202200006080A1 (en) 2022-03-28 2022-03-28 Oral solid composition for the management of neuropathic, osteo-articular, gynecological, post-surgical pain and mitochondrial trophism

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102022000006080A IT202200006080A1 (en) 2022-03-28 2022-03-28 Oral solid composition for the management of neuropathic, osteo-articular, gynecological, post-surgical pain and mitochondrial trophism

Publications (1)

Publication Number Publication Date
IT202200006080A1 true IT202200006080A1 (en) 2023-09-28

Family

ID=82308562

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102022000006080A IT202200006080A1 (en) 2022-03-28 2022-03-28 Oral solid composition for the management of neuropathic, osteo-articular, gynecological, post-surgical pain and mitochondrial trophism

Country Status (1)

Country Link
IT (1) IT202200006080A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103169695B (en) * 2013-02-05 2014-07-23 西安交通大学 Application of alpha-lipoic acid, acetyl-L-carnitine, coenzyme Q10 and hydroxytyrosol composition for preventing and treating amyotrophy
RU2701720C1 (en) * 2018-04-12 2019-10-01 Общество С Ограниченной Ответственностью "Валента - Интеллект" Combinations of palmitoylethanolamide for treating chronic pain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103169695B (en) * 2013-02-05 2014-07-23 西安交通大学 Application of alpha-lipoic acid, acetyl-L-carnitine, coenzyme Q10 and hydroxytyrosol composition for preventing and treating amyotrophy
RU2701720C1 (en) * 2018-04-12 2019-10-01 Общество С Ограниченной Ответственностью "Валента - Интеллект" Combinations of palmitoylethanolamide for treating chronic pain

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
ALESSANDRA PACINI ET AL.: "Comparative Assessment of the Activity of Racemic and Dextrorotatory Forms of Thioctic (Alpha-Lipoic) acid in Low Back pain: Clinical results and Clinical outcomes from an Open Randomized Trial", FRONT PHARMACOL., vol. 12, 24 February 2021 (2021-02-24), pages 607772
AMIT D KANDHARE ET AL.: "Polishing of molecular mechanism involved in neuroprotective effect of Coenzyme Q10 in alcohol-induced neuropathic pain", FUNDAM CLIN PHARMACOL., vol. 27, no. 6, 2 October 2012 (2012-10-02), pages 603 - 22
BEKIR BERKER ARTUKOGLU ET AL.: "Efficacy of Palmitoylethanolamide for pain: A Meta-Analysis", PAIN PHYSICIAN., vol. 20, no. 5, July 2017 (2017-07-01), pages 353 - 362
CHRISTIANE SCHULZUTE C OBERMU!!ER-JEVICOLIVER HASSELWANDERJURGEN BERNHARDTHANS K BIESALSKI: "Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilized (sulu Q10", INT J FOOD SCI NUTR, vol. 57, no. 7-8, November 2006 (2006-11-01), pages 546 - 55
DANIELA IMPELLIZZERI ET AL.: "Micronized/ultramicronized palmitoylethanolamide diplays outweighs or orai efficiency compared to non-micronized palmitoylethanolamide in a rat model of inflammatory pain", J NEUROINFLAMMATION., vol. 11, 28 August 2014 (2014-08-28), pages 136
ELIZABETH STEELSRUCHITHA VENKATESHELEANOR STEELSGEMMA VITETTALUIS VITETTA: "A double-blind randomized placebo-controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis", INFLAMMOPHARMACOLOGY, vol. 27, no. 3, 29 March 2019 (2019-03-29), pages 475 - 485, XP036801007, DOI: 10.1007/s10787-019-00582-9
EVANGELOS AGATHOS ET AL.: "Effect of a-lipoic acid on symptoms and quality of life in patients with pain diabetic neuropathy", J INT MEAN RES, vol. 46, no. 5, May 2018 (2018-05-01), pages 1779 - 1790
GUILLERMO LOPEZ-LLUCHJESUS DEL POZO-CRUZANA SACHEZ-CUESTAANA BELENCORTES-RODRIGUEZPLACIDO NAVAS: "Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization", NUTRITION, vol. 57, pages 133 - 140, XP085536397, DOI: 10.1016/j.nut.2018.05.020
HEMMI N BAGNAVARAJ K CHOPRO: "Plasma coenzyme Q10 response to orai ingestion of coenzyme Q10 formulations", MITOCHONDRION, vol. 7, June 2007 (2007-06-01), pages S78 - 88, XP022072331, DOI: 10.1016/j.mito.2007.03.003
HEMMI N BHAGAVANRAJ K CHOPRO: "Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics", FREE RADICAL RES, vol. 40, no. 5, May 2006 (2006-05-01), pages 445 - 53, XP009102744, DOI: 10.1080/10715760600617843
HUA QU ET AL.: "The effect of statin treatment on circulating coenzyme Q10 concentrations: An updated meta-analysis of randomized controlled trials", EUR J MED RES., vol. 23, 2018, pages 57
LINDA GABRIELSSONSOFIA MATTSSONCHRISTOPHER J FOWLER: "Palmitoylethanolamide for the treatment of pain: Pharmacokinetics, safety and efficacy", BR J CLIN PHARMACOL., vol. 82, no. 4, October 2016 (2016-10-01), pages 932 - 42, XP055452245, DOI: 10.1111/bcp.13020
LINDA RANKINCHRISTOPHER J FOWLER: "The Basai Pharmacology of Palmitoylethanolamide", INT J MOL SCI., vol. 21, no. 21, 26 October 2020 (2020-10-26), pages 7942
LUE ROCHETTESTELIANA GHIBUCAROLE RICHARDMARIANNE ZELLERYVES COTTINCATHERINE VERGHELY: "Direct and indirect antioxidizing properties of a-lipoic acid and therapeutic potential", MOL NUTR FOOD RES, vol. 57, no. 1, January 2013 (2013-01-01), pages 114 - 25
M PILAR VALDECENTOS ET AL.: "Lipoic acid improves mitochondrial function in nonalcoholic steatosis through the stimulation of syrtuin 1 and syrtuin 3", OBESITY (SILVER SPRING)., vol. 20, no. 10, 1 February 2012 (2012-02-01), pages 1974 - 83
MARIA LAVINIA BARTOLUCCI ET AL.: "Micronized palmitoylethanolamide reduces joint pain and glial celi activation", INFLAMM RES., vol. 67, no. 10, 18 August 2018 (2018-08-18), pages 891 - 901, XP036581605, DOI: 10.1007/s00011-018-1179-y
MARIO BRUFANI, ROCCO FIGLIOLA.: "(R)-a-lipoic acid liquid formulation:Pharmacokinetic parameters and therapeutic efficiency.", ACTA BIOMED, vol. 85, no. 2, 20 August 2014 (2014-08-20), pages 108 - 15
NASRIN SADEGHIYAN GALESHKALAMI ET AL.: "Alpha-lipoic acid and coenzyme Q10 combination ameliorates experimental diabetic neuropathy by modulating oxidative stress and apoptosis", LIFE SCIENCES., vol. 216, 1 January 2019 (2019-01-01), pages 101 - 11
PATEL SP, SULLIVAN PG, LYTTLE TS, RABCHEVSKY AG: "Acetyl-L-carnitines ameliorates mitochondrial function following contusion spinous cord injury", J NEUROCHEM., vol. 114, no. 1, 2010, pages 291 - 301
YAN PING ZHANG ET AL., ANESTHESIOLOGY, vol. 118, April 2013 (2013-04-01), pages 945 - 954
ZHENG-XIAN LIU , DEAR ARTMANN: "Relative bioavailability comparisonof different coenzyme Q10 formulated ons with a novel delivery system.", ALTERN THER HEALTH MED, vol. 15, no. 2, May 2009 (2009-05-01), pages 42 - 6

Similar Documents

Publication Publication Date Title
CL2017002709A1 (en) Compounds of pyrazolo - and triazolo - antiviral pyrimidine vs. vsr
PE20160045A1 (en) SOLUBLE AND STABILIZED RESPIRATORY SYNCITIAL VIRUS (RSV) PREFUSION POLYPEPTIDES F
CL2013000787A1 (en) Compounds derived from substituted fused benzamide, bradykinin receptor modulators; Pharmaceutical composition, useful in the treatment of acute, visceral, neuropathic pain, skin inflammation, among others.
JP1708482S (en) Confectionery
CL2020000002A1 (en) Crystalline form of n- [1- (5-cyano-pyridin-2-ylmethyl) -1h-pyrazol-3-yl] -2- [4- (1-trifluoromethyl-cyclopropyl) -phenyl] -acetamide.
IT202200006080A1 (en) Oral solid composition for the management of neuropathic, osteo-articular, gynecological, post-surgical pain and mitochondrial trophism
UY29517A1 (en) NEW CLASS OF 4-LACTAMA BENZONITRILOS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND APPLICATIONS
IT1400707B1 (en) USE OF ANTIBACTERIAL COMPOUNDS FOR ORAL CABLE HYGIENE
IT201900003009A1 (en) PRODUCT FOR ORAL HYGIENE
SV2016005309A (en) PROCESS OF OBTAINING AND PHARMACEUTICAL COMPOSITION FOR KETOROLACO TROMETAMINE AND SUBLINGUAL TRAMADOL CHLORHYDRATE USED FOR PAIN
IT202000000502A1 (en) Composition for the protection of the gastric mucosa.
CL2019003130A1 (en) Saccharides functionalized as anti-inflammatory agents.
IT201900025483A1 (en) Composition for disinfection of the oral cavity
DK3644970T3 (en) New oral formulations of belinostat
IT202200003869A1 (en) PRODUCT FOR ORAL HYGIENE
UA117045U (en) METHOD OF TREATMENT OF PERIODONTITIS
SG10201906474QA (en) Compositions and methods for the treatment of mucositis
JP1772045S (en) Confectionery
JP1754715S (en) confectionery
JP1754799S (en) confectionery
DOS2023000147S (en) CONFECTIONERY
DOS2023000148S (en) CONFECTIONERY
IT202200010178A1 (en) COMPOUND WITH THICKENING FUNCTION FOR PESTAL PRODUCTS
JP1749846S (en) sweets
JP1751164S (en) sweets